Home / Market News / $NKTR
benzinga Corporate Catalyst Impact 55/100 ● neutral

BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

Sep 28, 2026, 10:01 AM UTC · Primary ticker $NKTR

BTIG analyst Julian Harrison reiterated a Buy rating and maintained a $178 price target for Nektar Therapeutics. This filing indicates continued analyst confidence in the company, which could provide some positive sentiment for investors, though it's not new information.

This 8-K filing discloses that BTIG analyst Julian Harrison has reiterated a 'Buy' rating on Nektar Therapeutics (NKTR) and maintained a $178 price target. This action signifies that the analyst's view on the company's prospects and valuation remains unchanged. For traders, this is a moderate positive signal, as it confirms existing analyst support but does not introduce new information or a change in outlook. Short-term, it might prevent downward pressure on the stock by reinforcing investor confidence. Long-term, it suggests continued belief in the company's fundamentals by this particular analyst. The key opportunity for traders is to consider this reiteration as part of a broader mosaic of information when evaluating NKTR, especially if they are looking for confirmation of existing bullish theses.

$NKTR positive Analyst reiterates Buy rating and price target
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.